MCID: BLD048
MIFTS: 49

Bladder Transitional Cell Carcinoma malady

Nephrological, Cancer categories

Summaries for Bladder Transitional Cell Carcinoma

Sources:
33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MalaCards: Bladder Transitional Cell Carcinoma, also known as transitional cell carcinoma of bladder, is related to transitional cell carcinoma and bladder carcinoma. An important gene associated with Bladder Transitional Cell Carcinoma is CDKN1A (cyclin-dependent kinase inhibitor 1A (p21, Cip1)), and among its related pathways are Toll-like Receptor Pathway and HIF-1 signaling pathway. The compounds estrogen and hrgbeta1 have been mentioned in the context of this disorder. Affiliated tissues include whole blood, lymph node and brain, and related mouse phenotypes are no phenotypic analysis and cardiovascular system.

Aliases & Classifications for Bladder Transitional Cell Carcinoma

Sources:
8Disease Ontology, 10DISEASES, 45Novoseek, 61UMLS, 40NCIt, 57SNOMED-CT
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer
Anatomical: Nephrological


Aliases & Descriptions:

bladder transitional cell carcinoma 8 10
transitional cell carcinoma of bladder 8 61
urinary bladder urothelial carcinoma 8
carcinoma transitional cell bladder 45


External Ids:

Disease Ontology8 DOID:4006
NCIt40 C39851

Related Diseases for Bladder Transitional Cell Carcinoma

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Bladder Transitional Cell Carcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 89)
idRelated DiseaseScoreTop Affiliating Genes
1transitional cell carcinoma32.0IFI27, FABP4, UPK1A, EGFR, CDKN1A, ERBB2
2bladder carcinoma31.9TP53, ERBB2, CDKN1A
3adenocarcinoma30.3IFI27, EGFR, CDKN1A, MMP10, KRT13, ERBB2
4bladder transitional cell papilloma10.5
5transitional papilloma10.5
6prostate transitional cell carcinoma10.4
7clear cell adenocarcinoma10.3
8signet ring cell adenocarcinoma10.3
9pleomorphic carcinoma10.3
10spindle cell carcinoma10.3
11bladder signet ring cell adenocarcinoma10.3
12large cell carcinoma10.3
13bladder clear cell adenocarcinoma10.3
14inverted transitional papilloma10.3
15papillary carcinoma10.3
16papillary transitional carcinoma10.3
17sarcomatoid transitional cell carcinoma10.3
18bladder sarcoma10.3
19bladder urothelial papillary carcinoma10.3
20amyloidosis10.3
21bone carcinoma10.2
22prostate small cell carcinoma10.2
23small cell carcinoma10.2
24urethra transitional cell carcinoma10.2
25ovary transitional cell carcinoma10.2
26bladder adenocarcinoma10.2
27bladder disease10.2
28bladder diverticulum10.2
29ureter transitional cell carcinoma10.2
30gastrointestinal stromal tumor10.0IFI27
31cervical adenocarcinoma10.0CDKN1A, IFI27
32osteosarcoma10.0TP53, CDKN1A
33tongue cancer10.0CDKN1A
34leukoplakia10.0IFI27, KRT13
35esophageal cancer10.0TP53, EGFR
36laryngeal squamous cell carcinoma10.0IFI27, EGFR, CDKN1A, TP53
37uterine carcinosarcoma10.0ERBB2
38ductal carcinoma in situ10.0EGFR, ERBB2, TP53
39oral cavity cancer10.0TP53
40cervical intraepithelial neoplasia10.0IFI27
41cholesteatoma10.0KRT13
42oligodendroglioma10.0TP53, CDKN1A, EGFR
43laryngeal carcinoma10.0TP53, EGFR, IFI27
44papilloma10.0IFI27, CDKN1A, KRT13, TP53
45breast cancer, invasive ductal10.0CDKN1A, ERBB2, TP53
46neuroblastoma10.0TP53
47bladder carcinoma in situ10.0TP53, ERBB2, BLCAP, EGFR
48oral cancer10.0IFI27, EGFR, CDKN1A, KRT13, TP53
49lung cancer10.0EGFR, CDKN1A, ERBB2, TP53
50keratoacanthoma10.0CDKN1A

Graphical network of the top 20 diseases related to Bladder Transitional Cell Carcinoma:



Diseases related to bladder transitional cell carcinoma

Clinical Features for Bladder Transitional Cell Carcinoma

Drugs & Therapeutics for Bladder Transitional Cell Carcinoma

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials, 61UMLS, 41NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Bladder Transitional Cell Carcinoma

Drug clinical trials:

Search ClinicalTrials for Bladder Transitional Cell Carcinoma

Search NIH Clinical Center for Bladder Transitional Cell Carcinoma

Search CenterWatch for Bladder Transitional Cell Carcinoma

Genetic Tests for Bladder Transitional Cell Carcinoma

Anatomical Context for Bladder Transitional Cell Carcinoma

Sources:
33MalaCards
See all sources

MalaCards organs/tissues related to Bladder Transitional Cell Carcinoma:

33
Whole blood, Lymph node, Brain, Heart, Adipocyte, Kidney, Lung, Ovary, Prostate, Testis, Cervix, Monocytes, Dentritic cells, T cells, B cells, Endothelial

Animal Models for Bladder Transitional Cell Carcinoma or affiliated genes

Sources:
37MGI, 28inGenious Targeting Laboratory
See all sources

MGI Mouse Phenotypes related to Bladder Transitional Cell Carcinoma:

37
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000301210.3TP53, FGF3, CDKN1A, NR2F1, EGFR, HEPACAM
2MP:000538510.1TP53, FABP5, FABP4, EGFR, CDKN1A, HPGD
3MP:000537510.0FABP5, FABP4, EGFR, CDKN1A, TP53

Publications for Bladder Transitional Cell Carcinoma

Sources:
51PubMed
See all sources

Articles related to Bladder Transitional Cell Carcinoma:

(show top 50)    (show all 627)
idTitleAuthorsYear
1
Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma. (23609182)
2013
2
A case of unusual mast cell response with interstitial cystitis-like symptoms to neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder. (24335680)
2013
3
High-grade Transitional Cell Carcinoma of the Bladder in a 5-Year-Old Boy Successfully Treated With Partial Cystectomy and Intravesical Bacillus Calmette-Guerin. (23619109)
2013
4
Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: Case report and literature review. (22937482)
2012
5
Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. (21756352)
2011
6
Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder. (21976924)
2011
7
Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray. (21251473)
2011
8
Transitional cell carcinoma of the urinary bladder in a 14-year-old dog. (22131588)
2011
9
A one-port pneumovesicum method in en bloc laparoscopic nephroureterectomy with bladder cuff resection is feasible and safe for upper tract transitional cell carcinoma. (21481129)
2011
10
Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder. (21814319)
2011
11
Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. (19404918)
2009
12
Immunohistochemical positive stained p53 protein in bladder transitional cell carcinoma. (19332900)
2009
13
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. (18538698)
2008
14
The prognostic significance of pathologic stage T0 on organ-confined bladder transitional cell carcinoma following radical cystectomy. (19077398)
2008
15
Comparison of distributions of survivin among tissues from urinary bladders of dogs with cystitis, transitional cell carcinoma, or histologically normal urinary bladders. (18672973)
2008
16
Impaired delta NP63 expression is associated with poor tumor development in transitional cell carcinoma of the bladder. (18955789)
2008
17
The clinico-pathological significance of protein expression of PAK1 in bladder transitional cell carcinoma]. (18167251)
2007
18
EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. (17541304)
2007
19
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. (17011058)
2006
20
Survival and progression in high grade tumour subset of G2 and G3 pT1 bladder transitional cell carcinoma. (16784833)
2006
21
The detection of protein expression of clusterin and Ki-67 and the status of cell apoptosis in bladder transitional cell carcinoma]. (16620672)
2006
22
Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. (16642478)
2006
23
Heat shock protein 70 expression in relation to apoptosis in primary bladder transitional cell carcinoma. (16438908)
2005
24
Effect of retinoic acid and interferon alpha-2a on transitional cell carcinoma of bladder. (15592090)
2005
25
Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. (15833553)
2005
26
Significance of activated matrix metalloproteinase 2 (MMP2) in progression of bladder transitional cell carcinoma]. (12948424)
2003
27
Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. (12651606)
2003
28
Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. (11836589)
2002
29
p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder. (11464113)
2001
30
Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. (11115562)
2001
31
Isolation and characterization of the TERE1 gene, a gene down- regulated in transitional cell carcinoma of the bladder. (11314041)
2001
32
Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. (11712804)
2001
33
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? (11051255)
2000
34
Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. (10940702)
2000
35
Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. (11108659)
2000
36
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. (10070868)
1999
37
G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. (10376969)
1999
38
Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. (10197443)
1999
39
Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. (9477105)
1998
40
Re: Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. (9720567)
1998
41
Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. (9192993)
1997
42
p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. (9286659)
1997
43
The significance of E-cadherin in transitional-cell carcinoma of the human urinary bladder. (8738404)
1996
44
Immunohistochemical evaluation of nm23-H1 gene product in transitional cell carcinoma of the bladder. (8735718)
1996
45
The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. (8171764)
1993
46
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. (7677935)
1993
47
Comparative assessment of proliferating cell nuclear antigen immunostaining and of nucleolar organizer region staining in transitional cell carcinomas of the urinary bladder. Correlation with other conventional prognostic pathologic parameters. (1361436)
1992
48
Miliary tuberculosis secondary to transurethral bacillus Calmette-GuAcrin administration for superficial transitional cell carcinoma of the bladder. (2362292)
1990
49
Expression of CD15 antigen in urinary bladder transitional cell carcinoma. (1974266)
1990
50
Inverted papilloma of the bladder with focal transitional cell carcinoma: a case report. (3934592)
1985

Genetic Variations for Bladder Transitional Cell Carcinoma

Expression for genes affiliated with Bladder Transitional Cell Carcinoma

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Bladder Transitional Cell Carcinoma

Search GEO for disease gene expression data for Bladder Transitional Cell Carcinoma.

Pathways for genes affiliated with Bladder Transitional Cell Carcinoma

Sources:
60Tocris Bioscience, 30KEGG, 52QIAGEN, 38NCBI BioSystems Database, 12EMD Millipore, 53R&D Systems, 54Reactome, 56SinoBiological, 50PharmGKB
See all sources

Pathways related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show all 27)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Hide members
10.4ERBB2, TP53
210.4ERBB2, EGFR
3
Hide members
10.4ELK1, TP53
4
Hide members
10.4ELK1, EGFR
510.4TP53, EGFR, CDKN1A
6
Transcription Androgen Receptor nuclear signaling
Hide members
10.4CDKN1A, EGFR, ERBB2
710.4EGFR, CDKN1A, ERBB2
8
Hide members
10.4ELK1, CDKN1A, TP53
9
Development TGF-beta receptor signaling
Hide members
10.4CDKN1A, ELK1, ERBB2
10
Apoptosis and survival Apoptotic TNF-family pathways
Hide members
10.4CDKN1A, BIRC7, TP53
1110.4TP53, ERBB2, EGFR, CDKN1A
1210.4TP53, EGFR, CDKN1A, ERBB2
13
Hide members
10.4TP53, ERBB2, CDKN1A, EGFR
1410.4TP53, CDKN1A, ERBB2, EGFR
15
Hide members
10.4TP53, EGFR, ERBB2, CDKN1A
16
Hide members
10.4ERBB2, FGF3, EGFR, CDKN1A
17
Hide members
10.4EGFR, ERBB2, CDKN1A, FGF3
18
Hide members
10.4FGF3, ERBB2, CDKN1A, EGFR
1910.3TP53, ERBB2, EGFR, ELK1
20
Hide members
10.3ERBB2, ELK1, TP53, EGFR
21
Hide members
10.3TP53, ERBB2, FGF3, CDKN1A, EGFR
22
Hide members
10.3TP53, ELK1, ERBB2, CDKN1A, EGFR
23
Hide members
10.3TP53, CDKN1A, ELK1, EGFR, ERBB2
24
Hide members
10.3TP53, ERBB2, FGF3, EGFR, ELK1
2510.3FGF3, CDKN1A, ELK1, TP53, EGFR, ERBB2
2610.3EGFR, CDKN1A, FGF3, BIRC7, ERBB2, TP53
27
Hide members
10.3ERBB2, ELK1, EGFR, CDKN1A, FGF3, MMP10

Compounds for genes affiliated with Bladder Transitional Cell Carcinoma

Sources:
45Novoseek, 50PharmGKB, 11DrugBank, 60Tocris Bioscience, 24HMDB, 29IUPHAR
See all sources

Compounds related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 78)
idCompoundScoreTop Affiliating Genes
1estrogen4510.9NR2F1
2hrgbeta14510.8ERBB2, CDKN1A, EGFR
3taxane4510.8CDKN1A, EGFR, TP53, ERBB2
4suberoylanilide hydroxamic acid4510.8CDKN1A, EGFR, ERBB2, TP53
5oxaliplatin45 50 1112.8EGFR, TP53, CDKN1A, ERBB2
6flavopiridol45 1111.8ERBB2, EGFR, CDKN1A, TP53
7bortezomib45 1111.8ERBB2, CDKN1A, TP53, EGFR
8irinotecan45 50 1112.8ERBB2, TP53, CDKN1A, EGFR
9temozolomide45 1111.8EGFR, CDKN1A, TP53
10thymidylate4510.8EGFR, TP53, ERBB2, CDKN1A, IFI27
11gefitinib45 50 1112.7ERBB2, CDKN1A, EGFR, IFI27
12geldanamycin45 50 60 1113.7TP53, EGFR, CDKN1A, ERBB2
13gemcitabine45 50 1112.7ERBB2, CDKN1A, TP53, EGFR
14adpribose4510.7TP53, IFI27, CDKN1A, EGFR
15optimax4510.7IFI27, CDKN1A
16p000484510.7IFI27, CDKN1A
175fluorouracil4510.7CDKN1A, BIRC7, ERBB2, TP53, EGFR
18docetaxel45 50 60 1113.7EGFR, CDKN1A, ERBB2, TP53
19doxorubicin45 50 1112.7BIRC7, CDKN1A, TP53, EGFR, IFI27, ERBB2
20retinoid4510.7EGFR, TP53, CDKN1A, FABP12, FABP4, IFI27
21resveratrol45 60 11 2413.7ERBB2, CDKN1A, IFI27, TP53
22Afatinib1110.7EGFR, ERBB2
23paraffin4510.7IFI27, CDKN1A, EGFR, KRT13, ERBB2, TP53
24n acetylcysteine4510.7ERBB2, EGFR, TP53, IFI27, CDKN1A
25tamoxifen45 50 29 1113.7TP53, CDKN1A, EGFR, IFI27, ERBB2
26progesterone45 60 29 11 2414.7IFI27, EGFR, NR2F1, CDKN1A, ERBB2, HPGD
27paclitaxel45 50 1112.7TP53, ERBB2, CDKN1A, EGFR, IFI27
28indole-3-carbinol4510.7IFI27, CDKN1A, TP53
29cisplatin45 50 60 1113.7TP53, CDKN1A, EGFR, IFI27, BIRC7, ERBB2
30troglitazone45 29 60 1113.7KRT13, IFI27, FABP4, CDKN1A
31steroid4510.7ERBB2, FGF3, HPGD, FABP4, FABP5, IFI27
32vitamin d4510.7IFI27, CDKN1A, HPGD, KRT13, ERBB2
33mg 13245 6011.6IFI27, EGFR, CDKN1A, TP53
34vegf4510.6EGFR, IFI27, CDKN1A, FGF3, MMP10, ERBB2
35sulindac45 1111.6IFI27, TP53, CDKN1A
36batimastat45 60 1112.6EGFR, MMP10, ERBB2
37ly2940024510.6EGFR, CDKN1A, TP53, ERBB2, IFI27
38topotecan45 1111.6TP53, EGFR, ERBB2
39oligonucleotide4510.6NR2F1, CDKN1A, FGF3, MMP10, TP53, MZF1
40ag 1478 hydrochloride6010.6EGFR, ERBB2
41curcumin4510.6EGFR, CDKN1A, ERBB2, TP53
42ag 4906010.6EGFR, ERBB2
43jnj 28871063 hydrochloride6010.5ERBB2, EGFR
44retinoic acid45 2411.5ELK1, IFI27, FABP5, FABP4, FABP12, EGFR
45iressa6010.5EGFR, ERBB2
46pd1587804510.4EGFR, ERBB2
47pertuzumab45 50 1112.4ERBB2, EGFR
48serine4510.4ELK1, TP53, ERBB2, BIRC7, MMP10, HPGD
49n-(4-hydroxyphenyl)retinamide4510.3TP53, ERBB2, CDKN1A
50roscovitine4510.1TP53, CDKN1A, IFI27

GO Terms for genes affiliated with Bladder Transitional Cell Carcinoma

Sources:
16Gene Ontology
See all sources

Biological processes related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1phosphatidylinositol-mediated signalingGO:04801510.5EGFR, CDKN1A, FGF3, ERBB2
2neurotrophin TRK receptor signaling pathwayGO:04801110.5ELK1, ERBB2, FGF3, CDKN1A, EGFR
3fibroblast growth factor receptor signaling pathwayGO:00854310.4ERBB2, FGF3, CDKN1A, EGFR
4Fc-epsilon receptor signaling pathwayGO:03809510.4EGFR, CDKN1A, FGF3, ERBB2
5innate immune responseGO:04508710.3ELK1, ERBB2, FGF3, CDKN1A, EGFR
6epidermal growth factor receptor signaling pathwayGO:00717310.3ERBB2, FGF3, CDKN1A, EGFR
7mitotic cell cycle arrestGO:07185010.1CDKN1A, TP53

Molecular functions related to Bladder Transitional Cell Carcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1receptor signaling protein tyrosine kinase activityGO:00471610.4ERBB2, EGFR
2epidermal growth factor-activated receptor activityGO:00500610.1ERBB2, EGFR

Products for genes affiliated with Bladder Transitional Cell Carcinoma

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Bladder Transitional Cell Carcinoma

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet